| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04471415 2020-002770-27 Details | 2023-06-12 Interventional | 1/2 | 61 | Atezolizumab Carcinoma, Non-… Advanced Solid … Non Small Cell … | Company decision to closing study and discontinue further patient enrollment. - | |||
| NCT03174782 Details | 2023-06-12 Interventional | 4 | 42 | Bupivacaine Pain, Postopera… Postoperative P… | The study was terminated due to not enough power and research staff assistance. - | |||
| NCT02712905 Details | 2023-06-12 Interventional | 1/2 | 116 | Azacitidine Nivolumab Tretinoin Hematologic Neo… Neoplasms Solid Tumors an… | Strategic Business Decision The study was terminated by the sponsor due to a strategic business decision. | |||
| NCT02270632 Details | 2023-06-12 Interventional | 2 | 27 | Methotrexate Arthritis Arthritis, Rheu… Rheumatoid Arth… | Approvals of new agents for the same indication have significantly slowed down the recruitment
in this trial making the prosecution of the present investigation extremely difficult. - | |||
| NCT05135650 Details | 2023-06-09 Interventional | 1 | 20 | Antibodies Antibodies, Mon… Antineoplastic … Immunoglobulins Sotrovimab COVID-19 Neoplasms COVID-19 Infect… Hematopoietic a… Malignant Solid… | Terminated due to FDA withdrawal of the emergency use authorization (EUA) for sotrovimab - | |||
| NCT05423106 Details | 2023-06-08 Interventional | 1 | 60 | Entecavir Tenofovir Hepatitis B Hepatitis B, Ch… Healthy | Strategic business decision, not due to safety concerns - | |||
| NCT04649060 2019-002161-36 Details | 2023-06-08 Interventional | 3 | 54 | Daratumumab Dexamethasone Melphalan Multiple Myelom… Neoplasms, Plas… Relapsed Multip… Relapsed-Refrac… | The sponsor decided to terminate the study due to financial issues following an FDA request for
a partial clinical hold. This study was put on clinical hold and later discontinued prematurely. Due to this, there is limited data available, and data cleaning was not done according to the original plan. Due to the early termination, the response assessments were done by investigators, not by an independent review committee. | |||
| NCT04511650 Details | 2023-06-08 Interventional | 2 | 31 | Pharmaceutical … Acute Lung Inju… COVID-19 Coronavirus Inf… Respiratory Dis… Respiratory Dis… Acute Respirato… | After completion of Step 1 Part 1, the Sponsor discontinued the study based on challenges
associated with recruiting and monitoring patients in the current pandemic environment. - | |||
| NCT04348916 Details | 2023-06-08 Interventional | 1 | 66 | Pembrolizumab Breast Neoplasm… Carcinoma Colorectal Neop… Liver Neoplasms Neoplasm Metast… Neoplasms Squamous Cell C… Triple Negative… Advanced Solid … Breast Cancer Cancer Colorectal Carc… Liver Metastase… Melanoma Non-melanoma Sk… Solid Tumor Triple Negative… | Terminated due to Oncorus portfolio reprioritization - | |||
| NCT02246920 Details | 2023-06-08 Interventional | 3 | 1474 | Fluticasone Xhance Rhinitis Rhinitis, Aller… Rhinitis, Aller… Seasonal Allerg… | Development Halted - | |||
| NCT05564338 Details | 2023-06-07 Interventional | 3 | 0 | Tislelizumab Carcinoma Carcinoma, Hepa… Hepatocellular … | Study has voluntarily discontinued due to a change in the company-level development strategy
and is not because of any safety concern or the request from any health authority worldwide. - | |||
| NCT03896230 Details | 2023-06-07 Interventional | 4 | 11 | Ketamine Acute Pain Emergencies | Due to resource limitations the study was on hold and was then terminated. The study was initiated in 2019 and was then put on hold because of COVID. Post-COVID, the study was opened to enrollment again but due to limited resources and lack of enrollment, the study was terminated. | |||
| NCT03602976 Details | 2023-06-07 Interventional | 2 | 7 | Ursodeoxycholic… Sarcoidosis Hepatic Sarcoid… | Inability to adequately recruit subjects in COVID-19 pandemic Early termination due to poor recruitment in light of the COVID-19 pandemic, affecting data analysis. | |||
| NCT03192215 Details | 2023-06-07 Interventional | 3 | 1015 | Apixaban Aspirin Heart Diseases Ischemic Stroke Stroke | The DSMB halted the trial prematurely due to futility without any safety concerns. - | |||
| NCT02516670 Details | 2023-06-07 Interventional | 2 | 50 | Ascorbic Acid Docetaxel Vitamins Prostatic Neopl… Hormone-Resista… Metastatic Pros… Stage IV Prosta… | insufficient clinical response per DSMB - | |||
| NCT01370512 Details | 2023-06-07 Interventional | 2 | - | Droxidopa Pyridostigmine … Hypotension Hypotension, Or… Orthostatic Hyp… | Plan to increase enrollment due to preliminary data having lower statistical power than
anticipated. - | |||
| NCT04987996 Details | 2023-06-06 Interventional | 2 | 0 | Pembrolizumab Carcinoma Carcinoma, Squa… Melanoma Squamous Cell C… Head and Neck S… Metastatic Mela… | Study withdrawn due to lack of supply of one of the investigational agents. - | |||
| NCT04625699 Details | 2023-06-06 Interventional | 2 | 0 | Durvalumab Tremelimumab Carcinoma, Non-… Lung Neoplasms Nonsmall Cell L… | Contract was never finalized. - | |||
| NCT04502706 Details | 2023-06-05 Interventional | 1 | 9 | Rituximab Lymphoma Lymphoma, Non-H… Non-hodgkin Lym… | Sponsor's decision to discontinue development of this molecule - | |||
| NCT03859869 Details | 2023-06-05 Interventional | 4 | 1 | Pancreatin Pancrelipase Exocrine Pancre… Pancreatic Neop… Exocrine Pancre… | Business Considerations (difficulty with enrollment) This study was terminated due to low enrollment rates. The decision to terminate the study was not based on any safety or efficacy data. |